Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K D MillerL H Einhorn

Abstract

Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25% of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83%) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who failed to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy. VeIP has significant curative potential in patients with recurrent seminoma and appears to produce...Continue Reading

Citations

Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacqueline VukyRobert J Motzer
Aug 22, 2002·Bone Marrow Transplantation·O RickJ Beyer
Oct 14, 2005·Expert Review of Anticancer Therapy·Marcus L QuekDonald G Skinner
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan OldenburgSophie D Fosså
Jul 28, 2011·International Journal of Andrology·D KoychevF Honecker
May 14, 2016·Journal of Oncology Practice·Sawsan Rashdan, Lawrence H Einhorn
Nov 3, 2016·Nature Reviews. Urology·Matthew J MurrayNicholas Coleman
Feb 22, 2017·Current Oncology Reports·J Clayton AllenAlicia K Morgans
Feb 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vedang MurthyRobert Huddart
Apr 26, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Tsuneharu Miki, Masahiro Nakao
Feb 25, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Ugo De GiorgiGiovanni Rosti
Mar 10, 2005·Der Urologe. Ausg. A·M KuczykJ Beyer
Jun 11, 2010·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Emma J AlexanderAlan Horwich
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy D GilliganUNKNOWN American Society of Clinical Oncology
Aug 8, 2008·Current Opinion in Supportive and Palliative Care·Christian Kollmannsberger, Carsten Bokemeyer
Aug 7, 2010·Journal of the Chinese Medical Association : JCMA·Chung-King Lin, Han-Ting Liu
May 13, 2014·The Journal of Urology·Kevin R RiceRichard S Foster
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K N GanjooL H Einhorn
Sep 18, 2007·Der Urologe. Ausg. A·F vom DorpH Rübben
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchUNKNOWN German Testicular Cancer Study Group
May 14, 2009·Journal of Cancer Research and Clinical Oncology·Mountzios GiannisDimopoulos Meletios-Athanasios
Jan 18, 2007·The Oncologist·Guru SonpavdeBruce J Roth
Aug 20, 2008·Expert Opinion on Pharmacotherapy·C KollmannsbergerC Bokemeyer
Aug 9, 2011·Radiation Oncology·Noureddine BoujelbeneAbderrahim Zouhair
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria De SantisJörg Pont
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dany GholamChristine Theodore
Oct 14, 2006·Current Opinion in Urology·C J Logothetis
Mar 14, 2020·Current Opinion in Oncology·Jennifer KingLawrence H Einhorn
Sep 5, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M De SantisJ Pont
Dec 10, 1999·Seminars in Surgical Oncology·M F MilosevicP Warde
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W GeorgeLawrence H Einhorn
Oct 29, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S KregeUNKNOWN German Testicular Cancer Study Group (GTCSG)
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollUNKNOWN European Germ Cell Cancer Consensus Group
Jan 22, 2005·Critical Reviews in Oncology/hematology·Stefania GoriMaurizio Marangolo
Jul 13, 2021·Frontiers in Molecular Biosciences·Lude WangJianlie Yuan
Dec 19, 2003·The Urologic Clinics of North America·Manish I PatelJoel Sheinfeld
Jun 6, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer
Jun 3, 2011·European Urology·Peter AlbersUNKNOWN European Association of Urology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.